Dechra Pharmaceuticals Plc Stock Net Income
| DPHAYDelisted Stock | USD 93.78 0.00 0.00% |
Dechra Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Dechra Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Dechra Pink Sheet. The fundamental analysis module provides a way to measure Dechra Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dechra Pharmaceuticals pink sheet.
Dechra |
Dechra Pharmaceuticals PLC Company Net Income Analysis
Dechra Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Dechra Pharmaceuticals Net Income | 58.2 M |
Most of Dechra Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dechra Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Dechra Pharmaceuticals PLC reported net income of 58.2 M. This is 82.95% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The net income for all United States stocks is 89.81% higher than that of the company.
Dechra Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dechra Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Dechra Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Dechra Pharmaceuticals by comparing valuation metrics of similar companies.Dechra Pharmaceuticals is currently under evaluation in net income category among its peers.
Dechra Fundamentals
| Return On Equity | 0.0896 | |||
| Return On Asset | 0.0478 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 4.04 B | |||
| Shares Outstanding | 56.92 M | |||
| Shares Owned By Institutions | 0.09 % | |||
| Price To Book | 4.99 X | |||
| Price To Sales | 5.65 X | |||
| Revenue | 681.8 M | |||
| Gross Profit | 384.8 M | |||
| EBITDA | 178.9 M | |||
| Net Income | 58.2 M | |||
| Cash And Equivalents | 123.7 M | |||
| Cash Per Share | 2.29 X | |||
| Total Debt | 313.7 M | |||
| Debt To Equity | 0.49 % | |||
| Current Ratio | 2.91 X | |||
| Book Value Per Share | 12.30 X | |||
| Cash Flow From Operations | 122.9 M | |||
| Earnings Per Share | 1.29 X | |||
| Number Of Employees | 2 K | |||
| Beta | 0.68 | |||
| Market Capitalization | 4.3 B | |||
| Total Asset | 1.29 B | |||
| Z Score | 7.8 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 1.29 B | |||
| Last Dividend Paid | 0.45 |
About Dechra Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dechra Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dechra Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dechra Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Dechra Pink Sheet
If you are still planning to invest in Dechra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dechra Pharmaceuticals' history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |